Ironwood Pharmaceuticals is a leading gastrointestinal (GI) healthcare company on a mission to advance the treatment of GI diseases and redefine the standard of care for GI patients. The company is a pioneer in the development of LINZESS® (linaclotide), the U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). In June 2023, the U.S. Food and Drug Administration also approved LINZESS for the treatment of functional constipation in pediatric patients ages 6-17 years-old. Under the guidance of its seasoned industry leaders, Ironwood continues to build upon its history of GI innovation and challenge what has been done before to shape what the future holds. The company keeps patients at the heart of its R&D and commercialization efforts to reduce the burden of GI diseases and address significant unmet needs.